|
|
 |
|
Viewing report
|
|
|
Targacept, Inc.
Sheila Greco Associates, May 2011, Pages: 1
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept`s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer`s disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, multiple preclinical programs, and strategic alliances with AstraZeneca and GlaxoSmithKline.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
